On November 4, 2021 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported that it has negotiated an amendment to its Licence Agreement for the Company’s focal adhesion kinase (FAK) asset AMP886 (Press release, Amplia Therapeutics, NOV 4, 2021, View Source;[email protected] [SID1234594632]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the initial Licence Agreement signed in March 2018 between the Company and Cancer Research UK (CRUK), the Company agreed to either file an Investigational New Drug application (IND) or initiate a Phase 1 clinical trial of AMP886 within 3 years. In March 2021, CRUK agreed to extend the term allowed for initiation of these activities, subject to further negotiations with the Company. CRUK has now agreed to extend the deadline for filing an IND or commencing a Phase 1 trial of AMP886 until 31 December 2023.

Amplia’s CEO Dr John Lambert commented that "We are extremely pleased that we have been able to obtain this extension from CRUK and are grateful for their support and collaboration on this matter. The additional time that has been made available will allow us to undertake further preclinical studies with this promising molecule which has a unique activity profile, and identify therapeutic indications for which it is best suited before we initiate formal development. Meanwhile, our efforts to push AMP945 onward into Phase 2 trials are proceeding in earnest."

This ASX announcement has been approved and authorised for release by the CEO of Amplia Therapeutics.